HK1187915A1 - 1,4 oxazines as bace1 and/or bace2 inhibitors bace1 / bace2 14 - Google Patents
1,4 oxazines as bace1 and/or bace2 inhibitors bace1 / bace2 14Info
- Publication number
- HK1187915A1 HK1187915A1 HK14101028.8A HK14101028A HK1187915A1 HK 1187915 A1 HK1187915 A1 HK 1187915A1 HK 14101028 A HK14101028 A HK 14101028A HK 1187915 A1 HK1187915 A1 HK 1187915A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bace1
- bace2
- oxazines
- inhibitors
- bace2 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11153095 | 2011-02-02 | ||
PCT/EP2012/051481 WO2012104263A2 (en) | 2011-02-02 | 2012-01-31 | 1,4 oxazines as bace1 and/or bace2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1187915A1 true HK1187915A1 (en) | 2014-04-17 |
Family
ID=45562303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14101028.8A HK1187915A1 (en) | 2011-02-02 | 2014-01-30 | 1,4 oxazines as bace1 and/or bace2 inhibitors bace1 / bace2 14 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8399459B2 (xx) |
EP (1) | EP2670738A2 (xx) |
JP (1) | JP2014507427A (xx) |
KR (1) | KR20140019340A (xx) |
CN (1) | CN103339117B (xx) |
BR (1) | BR112013014610A2 (xx) |
CA (1) | CA2817841A1 (xx) |
HK (1) | HK1187915A1 (xx) |
MX (1) | MX2013007957A (xx) |
RU (1) | RU2013137814A (xx) |
WO (1) | WO2012104263A2 (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
ES2476605T3 (es) | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
JP5490692B2 (ja) | 2008-06-13 | 2014-05-14 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
JPWO2012147763A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
AU2012322329A1 (en) | 2011-10-13 | 2014-05-01 | Novartis Ag | Novel oxazine derivatives and their use in the treatment of disease |
WO2013161929A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物 |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
CN104130204B (zh) * | 2014-07-03 | 2016-04-27 | 浙江大学 | 一种制备n-磺酰基-1,4-噁嗪类衍生物的方法 |
CA2979113A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
BRPI0907563A2 (pt) | 2008-02-18 | 2015-08-04 | Hoffmann La Roche | Derivados de 4,5-di-hidro-xazol-2-il amina |
AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
JP5711813B2 (ja) * | 2010-06-09 | 2015-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | βセクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−2H−[1,4]オキサジン−3−イル−アミン誘導体 |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
-
2012
- 2012-01-25 US US13/357,640 patent/US8399459B2/en not_active Expired - Fee Related
- 2012-01-31 WO PCT/EP2012/051481 patent/WO2012104263A2/en active Application Filing
- 2012-01-31 RU RU2013137814/04A patent/RU2013137814A/ru not_active Application Discontinuation
- 2012-01-31 KR KR1020137023053A patent/KR20140019340A/ko not_active Application Discontinuation
- 2012-01-31 EP EP12702227.5A patent/EP2670738A2/en not_active Withdrawn
- 2012-01-31 BR BR112013014610A patent/BR112013014610A2/pt not_active IP Right Cessation
- 2012-01-31 CN CN201280007173.5A patent/CN103339117B/zh not_active Expired - Fee Related
- 2012-01-31 MX MX2013007957A patent/MX2013007957A/es unknown
- 2012-01-31 JP JP2013552168A patent/JP2014507427A/ja active Pending
- 2012-01-31 CA CA2817841A patent/CA2817841A1/en not_active Abandoned
-
2014
- 2014-01-30 HK HK14101028.8A patent/HK1187915A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN103339117A (zh) | 2013-10-02 |
RU2013137814A (ru) | 2015-03-10 |
JP2014507427A (ja) | 2014-03-27 |
US20120196863A1 (en) | 2012-08-02 |
CA2817841A1 (en) | 2012-08-09 |
US8399459B2 (en) | 2013-03-19 |
WO2012104263A2 (en) | 2012-08-09 |
WO2012104263A3 (en) | 2012-09-27 |
BR112013014610A2 (pt) | 2016-09-20 |
EP2670738A2 (en) | 2013-12-11 |
MX2013007957A (es) | 2013-08-01 |
KR20140019340A (ko) | 2014-02-14 |
CN103339117B (zh) | 2015-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL228104A0 (en) | 3, 1 oxazolines as 1bace and/or 2bace inhibitors | |
IL229686A0 (en) | Halogen-alkyl-3,1 oxazines as 1bace and/or bacce2 inhibitors | |
HK1187915A1 (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors bace1 / bace2 14 | |
ZA201308400B (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
IL229334A0 (en) | Spiro-[3,1]-oxazines and spiro-[4,1]-oxazapines as 2bace and/or 1bace inhibitors | |
HK1210609A1 (en) | Fluoro-[1,3]oxazines as bace1 inhibitors bace1 -[13] | |
IL262493B (en) | Methylphenidate-medications, processes for their preparation and use | |
BR112013016360A2 (pt) | 1,4 oxazinas como inibidores de bace1 e/ou bace2 | |
EP2747769A4 (en) | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND USE THEREOF | |
EP2697210A4 (en) | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONOXIDES AND DIOXIDES AS BACE INHIBITORS, THEIR COMPOSITIONS AND THEIR USE | |
SG11201406123TA (en) | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS | |
EP2703399A4 (en) | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF | |
HK1190701A1 (zh) | 作為 和/或 抑制劑的 -氨基- -四氫- -二氧雜- -氮雜-茚- -基 -苯基 -酰胺 | |
BR112013020019A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2. | |
EP2694070A4 (en) | COMBINATIONS OF ACT-HEMMER COMPOUNDS AND ERLOTINIB AND METHOD OF USE THEREOF | |
IL232764A0 (en) | Fluoromethyl-6,5- - dihydro-1,34]-h]oxazine | |
EP2729464B8 (en) | Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors | |
IL235681A (en) | 5-amino [1, 4] thiazines as 1bace inhibitors | |
IL236138A (en) | Dipluoro-hexahydro-cyclophenoxazinyls and diplooro-hexahydro-benzooxazinyls as bace inhibitors1 | |
IL229262A0 (en) | Superstructure and methods for its production | |
GB201108825D0 (en) | Morpholino compounds, uses and methods | |
ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
HK1191942A1 (zh) | 新型六氫環戊二烯並吡咯酮,六氫吡咯並吡咯酮,八氫吡咯並吡啶酮和八氫吡啶酮化合物 | |
ZA201309171B (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
ZA201306276B (en) | Sporulation-deficient b.texasporus cells and methods for efficient and cost-effective inactivation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190129 |